Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

51 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
T lymphocyte proliferation is suppressed by the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases.
Zagon IS, Donahue RN, Bonneau RH, McLaughlin PJ. Zagon IS, et al. Among authors: donahue rn. Immunobiology. 2011 May;216(5):579-90. doi: 10.1016/j.imbio.2010.09.014. Epub 2010 Sep 29. Immunobiology. 2011. PMID: 20965606
Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer.
Zagon IS, Donahue R, McLaughlin PJ. Zagon IS, et al. Exp Biol Med (Maywood). 2013 May;238(5):579-87. doi: 10.1177/1535370213488483. Exp Biol Med (Maywood). 2013. PMID: 23856908
Under-expression of the opioid growth factor receptor promotes progression of human ovarian cancer.
Donahue RN, McLaughlin PJ, Zagon IS. Donahue RN, et al. Exp Biol Med (Maywood). 2012 Feb;237(2):167-77. doi: 10.1258/ebm.2011.011321. Epub 2012 Feb 10. Exp Biol Med (Maywood). 2012. PMID: 22328595
Expression of the opioid growth factor-opioid growth factor receptor axis in human ovarian cancer.
Fanning J, Hossler CA, Kesterson JP, Donahue RN, McLaughlin PJ, Zagon IS. Fanning J, et al. Among authors: donahue rn. Gynecol Oncol. 2012 Feb;124(2):319-24. doi: 10.1016/j.ygyno.2011.10.024. Epub 2011 Oct 28. Gynecol Oncol. 2012. PMID: 22037317
Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model.
Donahue RN, McLaughlin PJ, Zagon IS. Donahue RN, et al. Exp Biol Med (Maywood). 2011 Sep;236(9):1036-50. doi: 10.1258/ebm.2011.011121. Epub 2011 Aug 1. Exp Biol Med (Maywood). 2011. PMID: 21807817
Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin.
Donahue RN, McLaughlin PJ, Zagon IS. Donahue RN, et al. Exp Biol Med (Maywood). 2011 Jul;236(7):883-95. doi: 10.1258/ebm.2011.011096. Epub 2011 Jun 17. Exp Biol Med (Maywood). 2011. PMID: 21685240
The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice.
Donahue RN, McLaughlin PJ, Zagon IS. Donahue RN, et al. Gynecol Oncol. 2011 Aug;122(2):382-8. doi: 10.1016/j.ygyno.2011.04.009. Epub 2011 Apr 30. Gynecol Oncol. 2011. PMID: 21531450
B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases.
Zagon IS, Donahue RN, Bonneau RH, McLaughlin PJ. Zagon IS, et al. Among authors: donahue rn. Immunobiology. 2011 Jan-Feb;216(1-2):173-83. doi: 10.1016/j.imbio.2010.06.001. Epub 2010 Jun 11. Immunobiology. 2011. PMID: 20598772
Regulation of Tenon's capsule fibroblast cell proliferation by the opioid growth factor and the opioid growth factor receptor axis.
Klocek MS, Sassani JW, Donahue RN, McLaughlin PJ, Zagon IS. Klocek MS, et al. Among authors: donahue rn. Invest Ophthalmol Vis Sci. 2010 Oct;51(10):5054-61. doi: 10.1167/iovs.09-4949. Epub 2010 May 12. Invest Ophthalmol Vis Sci. 2010. PMID: 20463323 Free PMC article.
The opioid growth factor-opioid growth factor receptor axis regulates cell proliferation of human hepatocellular cancer.
Avella DM, Kimchi ET, Donahue RN, Tagaram HR, McLaughlin PJ, Zagon IS, Staveley-O'Carroll KF. Avella DM, et al. Among authors: donahue rn. Am J Physiol Regul Integr Comp Physiol. 2010 Feb;298(2):R459-66. doi: 10.1152/ajpregu.00646.2009. Epub 2009 Nov 18. Am J Physiol Regul Integr Comp Physiol. 2010. PMID: 19923357 Free PMC article.
51 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback